7 results on '"Elisa Fiorentini"'
Search Results
2. Comparison of ultrasound attenuation by calcium pyrophosphate, hydroxyapatite and monosodium urate crystals: a proof-of-concept study
- Author
-
Georgios Filippou, Giovanni Pacini, Silvia Sirotti, Matthias Zadory, Davide Carboni, Arianna Damiani, Elisa Fiorentini, Edoardo Cipolletta, Emilio Filippucci, Johannes M Froehlich, Piercarlo Sarzi Puttini, and Fabio Becce
- Subjects
Durapatite ,Gout ,Rheumatology ,Immunology ,Humans ,Immunology and Allergy ,Chondrocalcinosis ,Calcium Pyrophosphate ,General Biochemistry, Genetics and Molecular Biology ,Uric Acid - Published
- 2022
3. Fecal microbiome in systemic sclerosis, in search for the best candidate for microbiota-targeted therapy for small intestinal bacterial overgrowth control
- Author
-
Elisa Fiorentini, Edda Russo, Amedeo Amedei, and Silvia Bellando Randone
- Subjects
Rheumatology ,Immunology ,Immunology and Allergy - Abstract
Gastrointestinal involvement is a common complication in systemic sclerosis patients and must be suspected and investigated already in the early stages of the disease. Gastrointestinal symptoms and complications—such as gastroesophageal reflux disease, intestinal pseudo-obstruction, malnutrition, diarrhea, constipation, and small intestinal bacterial overgrowth—severely impair systemic sclerosis patients’ quality of life and affect their prognosis. Although some pathogenetic aspects of the gastrointestinal involvement in systemic sclerosis remain unclear, defining the characteristics of the microbiota and its role could help in risk stratification, selection of candidates for microbiota-targeted therapies, prediction of standard treatment efficacy, and prognosis of systemic sclerosis patients. Finally, understanding how to modify the microbiota composition may represent an important therapeutic approach to target gastrointestinal involvement in systemic sclerosis.
- Published
- 2022
4. The Yin-Yang Pharmacomicrobiomics on Treatment Response in Inflammatory Arthritides: A Narrative Review
- Author
-
Silvia Peretti, Sara Torracchi, Edda Russo, Francesco Bonomi, Elisa Fiorentini, Khadija El Aoufy, Cosimo Bruni, Gemma Lepri, Martina Orlandi, Maria Sole Chimenti, Serena Guiducci, Amedeo Amedei, Marco Matucci-Cerinic, and Silvia Bellando Randone
- Subjects
Genetics ,Genetics (clinical) - Abstract
(1) Background: Gut microbiota (GM) is the set of microorganisms inhabiting the gastroenteric tract that seems to have a role in the pathogenesis of rheumatic diseases. Recently, many authors proved that GM may influence pharmacodynamics and pharmacokinetics of several drugs with complex interactions that are studied by the growing field of pharmacomicrobiomics. The aim of this review is to highlight current evidence on pharmacomicrobiomics applied to the main treatments of Rheumatoid Arthritis and Spondyloarthritis in order to maximize therapeutic success, in the framework of Personalized Medicine. (2) Methods: We performed a narrative review concerning pharmacomicrobiomics in inflammatory arthritides. We evaluated the influence of gut microbiota on treatment response of conventional Disease Modifying Anti-Rheumatic drugs (cDMARDs) (Methotrexate and Leflunomide) and biological Disease Modifying Anti-Rheumatic drugs (bDMARDs) (Tumor necrosis factor inhibitors, Interleukin-17 inhibitors, Interleukin 12/23 inhibitors, Abatacept, Janus Kinase inhibitors and Rituximab). (3) Results: We found a great amount of studies concerning Methotrexate and Tumor Necrosis Inhibitors (TNFi). Conversely, fewer data were available about Interleukin-17 inhibitors (IL-17i) and Interleukin 12/23 inhibitors (IL-12/23i), while none was identified for Janus Kinase Inhibitors (JAKi), Tocilizumab, Abatacept and Rituximab. We observed that microbiota and drugs are influenced in a mutual and reciprocal way. Indeed, microbiota seems to influence therapeutic response and efficacy, whereas in the other hand, drugs may restore healthy microbiota. (4) Conclusions: Future improvement in pharmacomicrobiomics could help to detect an effective biomarker able to guide treatment choice and optimize management of inflammatory arthritides.
- Published
- 2022
5. Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data
- Author
-
Elisa Fiorentini, Francesco Bonomi, Silvia Peretti, Martina Orlandi, Gemma Lepri, Marco Matucci Cerinic, Silvia Bellando Randone, and Serena Guiducci
- Subjects
Space and Planetary Science ,Paleontology ,General Biochemistry, Genetics and Molecular Biology ,Ecology, Evolution, Behavior and Systematics - Abstract
Background: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is one of the most relevant complications of SSc and the major cause of death. The pathogenesis of SSc-ILD involves a complex interplay of multiple cell types and different molecular pathways, with both inflammation and fibrosis as pathological hallmarks. To date, there are no treatments able to target both components of the disease. Janus kinase inhibitors (JAKinibs) represent an interesting therapeutic option because they exert both anti-inflammatory and anti-fibrotic properties. Methods: Here, we performed a narrative review concerning the potential role of JAKinibs in SSc-ILD to define the state of art and to evaluate the pathogenetic rationale behind this type of treatment. Results: Currently, few studies investigated SSc-ILD response to JAKinibs treatment. Data were analyzed from three clinical studies and four case reports and progression of SSc-ILD was not evident in 93.5% of patients treated with JAKinibs. Conclusions: Available evidence of efficacy of JAKinibs in SSc-ILD is sparse but promising. JAKinibs could be an interesting treatment in SSc-ILD because of their potential inhibition of the fibrotic processes combined with their anti-inflammatory action. Moreover, JAKinibs were also shown in some studies to have a potential effect on pulmonary arterial hypertension (PAH), another threatening complication in SSc. More data are necessary to define JAKinibs role in SSc-ILD treatment.
- Published
- 2022
6. Radical remodeling of the Y chromosome in a recent radiation of malaria mosquitoes
- Author
-
Changde Cheng, Matthew W. Hahn, Simo V. Zhang, Philippos Aris Papathanos, Nora J. Besansky, Jonathan Hnath, Xiaofang Jiang, Maria V. Sharakhova, Elisa Fiorentini, Scott J. Emrich, Nikolai Windbichler, Aaron Steele, Tania Dottorini, Nicholas H. Bergman, Diane Radune, Igor V. Sharakhov, Adam M. Phillippy, Zhijian Jake Tu, Roberto Galizi, Atashi Sharma, Omar S. Akbari, Lauren A. Assour, Sergey Koren, Tony Nolan, Alessia Cagnetti, Vladimir A. Timoshevskiy, Andrew Brantley Hall, and Andrea Crisanti
- Subjects
0301 basic medicine ,Male ,Anopheles gambiae ,Genome, Insect ,Q1 ,Genome ,HETEROCHROMATIN ,Pacbio ,RNA-Seq ,Tandem repetitive DNA ,Y-chromosome ,Animals ,Anopheles ,Chromosomes, Insect ,Female ,Insect Vectors ,Malaria ,Phylogeny ,Sequence Analysis, DNA ,X Chromosome ,Y Chromosome ,2.2 Factors relating to the physical environment ,Aetiology ,X chromosome ,PacBio ,Genetics ,Multidisciplinary ,GENOME ,Y-хромосома ,Mosquito control ,Infectious Diseases ,PNAS Plus ,ANOPHELES-GAMBIAE COMPLEX ,DROSOPHILA-MELANOGASTER ,SATELLITE DNA ,SEX-CHROMOSOMES ,EVOLUTION ,GENE ,SEQUENCES ,STEPHENSI ,Infection ,Sequence Analysis ,Biotechnology ,Heterochromatin ,Satellite DNA ,1.1 Normal biological development and functioning ,малярийные комары ,Biology ,Y chromosome ,Chromosomes ,03 medical and health sciences ,Rare Diseases ,Underpinning research ,parasitic diseases ,tandem repetitive DNA ,Gene ,Human Genome ,DNA ,Sex Determination Processes ,biology.organism_classification ,Vector-Borne Diseases ,Good Health and Well Being ,030104 developmental biology ,Insect - Abstract
Y chromosomes control essential male functions in many species, including sex determination and fertility. However, because of obstacles posed by repeat-rich heterochromatin, knowledge of Y chromosome sequences is limited to a handful of model organisms, constraining our understanding of Y biology across the tree of life. Here, we leverage long single-molecule sequencing to determine the content and structure of the nonrecombining Y chromosome of the primary African malaria mosquito, Anopheles gambiae. We find that the An. gambiae Y consists almost entirely of a few massively amplified, tandemly arrayed repeats, some of which can recombine with similar repeats on the X chromosome. Sex-specific genome resequencing in a recent species radiation, the An. gambiae complex, revealed rapid sequence turnover within An. gambiae and among species. Exploiting 52 sex-specific An. gambiae RNA-Seq datasets representing all developmental stages, we identified a small repertoire of Y-linked genes that lack X gametologs and are not Y-linked in any other species except An. gambiae, with the notable exception of YG2, a candidate male-determining gene. YG2 is the only gene conserved and exclusive to the Y in all species examined, yet sequence similarity to YG2 is not detectable in the genome of a more distant mosquito relative, suggesting rapid evolution of Y chromosome genes in this highly dynamic genus of malaria vectors. The extensive characterization of the An. gambiae Y provides a long-awaited foundation for studying male mosquito biology, and will inform novel mosquito control strategies based on the manipulation of Y chromosomes.
- Published
- 2016
7. Effects of Osteogenic Differentiation Inducers on in Vitro Expanded Adult Mesenchymal Stromal Cells
- Author
-
Nicola Baldini, Donatella Granchi, Elisa Leonardi, Gabriela Ciapetti, Elisa Fiorentini, Fiorentini E, Granchi D, Leonardi E, Baldini N, and Ciapetti G
- Subjects
Male ,Biomedical Engineering ,Medicine (miscellaneous) ,Bioengineering ,Ascorbic Acid ,Biology ,Collagen Type I ,Dexamethasone ,OSTEOBLAST DIFFERENTIATION ,Biomaterials ,Osteogenesis ,Humans ,Inducer ,Bone regeneration ,Cells, Cultured ,Aged ,Cell Proliferation ,Cell growth ,Mesenchymal stem cell ,Cell Differentiation ,MESENCHYMAL STEM CELLS ,General Medicine ,Middle Aged ,Alkaline Phosphatase ,In vitro ,Cell biology ,Glycerophosphates ,Immunology ,Female ,Stem cell ,Ex vivo - Abstract
Purpose For bone regeneration therapy using stem cells, well-defined ex vivo protocols to expand mesenchymal stromal cells (MSC), as well as assays to show their potential differentiation into the osteogenic lineage, are needed. Aim of this study was to analyze the role of the biochemical osteogenic inducers, i.e. ascorbic acid, dexamethasone, and β-glycerophosphate, employed in the current protocols for osteogenic differentiation of MSC in vitro, to address the requirements for reliable differentiation systems. Methods MSC were isolated from the bone marrow of donors (46–73 years of age) undergoing total hip replacement, and expanded in vitro. At confluence, MSC were cultured under four different conditions: α-MEM plus serum (basal medium or C1), basal medium plus ascorbate (C2), basal medium plus ascorbate and dexamethasone (C3), or basal medium plus ascorbate, dexamethasone and β-glycerophosphate (C4). Morphology, proliferation, mineralization, alkaline phosphatase, collagen and expression of bone-related genes of MSC under the different media were analyzed at fixed time points. Results MSC proliferation and the number of colony forming units were increased by ascorbic acid, whereas dexamethasone enhanced the proportion of ALP-positive CFU and was critical for mineral deposition. Runx-2 and type I collagen gene expression decreased along with additive-induced MSC differentiation, i.e. from C1 to C4, while ALP and osteocalcin were differently regulated. Conclusion Our findings support the role of different inducers on the sequential stages of MSC expansion and osteogenic differentiation in vitro, suggesting the addition of DEX following proliferation to ensure mineralization, as an index of in vivo osteogenic potency of human mesenchymal cells.
- Published
- 2011
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.